Diuretics: A review and update

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2014, Pages 5-13

  Roush, George C ^a   Kaur, Ramdeep ^a   Ernst, Michael E ^b  

^a ST VINCENT S MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

cardiac pharmacology; cardiovascular disease; cerebrovascular disease; congestive heart failure; diuretics; hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ARGININE VASOPRESSIN RECEPTOR ANTAGONIST; AZOSEMIDE; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; HORMONE RECEPTOR BLOCKING AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; PLACEBO; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; EVENING DOSAGE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; HYPERVOLEMIA; LIFE EXPECTANCY; MORNING DOSAGE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SUDDEN CARDIAC DEATH; SURVIVAL; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARDIAC PHARMACOLOGY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIURETICS; HYPERTENSION;

AGED, 80 AND OVER; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD VOLUME; CLINICAL TRIALS AS TOPIC; DIURETICS; DRUG DESIGN; HUMANS; HYPERTENSION; TIME FACTORS; WATER-ELECTROLYTE IMBALANCE;

EID: 84890932782     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413497257     Document Type: Review

References (50)

1. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J. 1992 ; 13 (suppl G). 28-33
2. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009 ; 94 (4). 1361-1366
3. Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012 ; 60 (2). 319-325
4. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003 ; 289 (19). 2534-2544
5. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009 ; (3). CD001841
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiologic studies. BMJ. 2009 ; 338: b1665
7. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011 ; 57 (4). 689-694
8. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012 ; 59 (6). 1110-1117
9. Top 20 U.S. Pharmaceutical Products by Dispensed Prescriptions. Danbury, CT: IMS ; 2011 :
10. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens. 2010 ; 12 (12). 927-934
11. Kuehlein T, Lauz G, Gutscher A, Goetz K, Szecseny J. Diuretics for hypertension: an inconsistency in primary care prescribing behavior. Curr Med Res Opin. 2011 ; 27 (3). 497-502
12. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006 ; 47 (3). 352-358
13. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 ; 125: 12 e1-1229
14. Ernst ME, Neaton JD, Grimm RH, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011 ; 58 (6). 1001-1007
15. Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension: a population-based cohort study. Ann Intern Med. 2013 ; 158 (6). 447-455
16. Psaty BM, Lumley T, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004 ; 292 (1). 43-44
17. Elliott WJ, Childers WK, Meyer PM. Poster PO-91: outcomes with different diuretics in clinical trials in hypertension: results of network and Bayesian meta-analyses. J Clin Hypertension. 2012 ; 14: suppl
18. Calhoun DA, Jones D, Textor S, et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 ; 117 (25). e510 - e526
19. Flack JM, Sica DA, Bakris G, et al. Society on Hypertension in Blacks Consensus Statement Management of High Blood Pressure in Blacks: an Update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010 ; 56: 78-800
20. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. BMJ. 2011 ; 343: d4891
21. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011 ; 306 (23). 2588-2593
22. Cushman WC, Davis BR, Pressel SL, et al. ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012 ; 14 (1). 20-31
23. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 ; 358 (18). 1887-1898
24. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 ; 364 (1). 11-21
25. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 ; 341 (10). 709-717
26. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013 ; 309 (8). 781-791
27. Adamopoulos C, Ahmed A, Fay R, et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart fail. 2009 ; 11 (11). 1099-1105
28. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348 (14). 1309-1321
29. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010 ; 33 (9). 572-577
30. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med. 2008 ; 56 (4). 714-719
31. Nielsen SE, Persson F, Frandsen E, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012 ; 29 (8). e184 - e190
32. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin- aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008 ; 31 (1). 59-67
33. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 ; 52 (3). 486-493
34. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockadewith eplerenone in non-diabetic chronic kidney disease. Arandomized cross-over study. PLoS One. 2011 ; 6 ( 11 ):
35. Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011 ; 29 (5). 980-990
36. Hisatake S, Nanjo S, Fujimoto S, et al. Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123)I-metaiodobenzylguanidine scintigraphy. Eur J Heart Fail. 2011 ; 13 (8). 892-898
37. Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012 ; 76 (4). 833-842
38. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure?. Future Cardiol. 2012 ; 8 (5). 707-728
39. Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O'Connor CM. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010 ; 105 (12). 1794-1797
40. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 ; 364 (9). 797-805
41. Hermida RC, Ayala DE, Mojón A, et al. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int. 2008 ; 25 (6). 950-970
42. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011 ; 13 (9). 639-643
43. Sanjay S, Annigeri RA, Seshadri R, Rao BS, Prakash KC, Mani MK. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease. Nephrology (Carlton). 2008 ; 13 (3). 247-250
44. Hermida RC, Ayala DE, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int. 2010 ; 27 (8). 1629-1651
45. Hermida RC, Ayala DE, Mojón A. Fernández JR Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol Int. 2013 ; 30 (1-2). 315-327
46. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011 ; 25 (suppl 1). S57 - S65
47. Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011 ; 17 (12). 973-981
48. Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail. 2011 ; 17 (12). 982-989
49. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010 ; 53 (2). 283-290
50. Ginès P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010 ; 31 (8). 834-845